for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Fennec Pharmaceuticals Inc

FENC.OQ

Latest Trade

4.89USD

Change

-0.01(-0.20%)

Volume

7,211

Today's Range

4.88

 - 

4.91

52 Week Range

3.26

 - 

8.59

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
4.90
Open
4.91
Volume
7,211
3M AVG Volume
1.42
Today's High
4.91
Today's Low
4.88
52 Week High
8.59
52 Week Low
3.26
Shares Out (MIL)
19.90
Market Cap (MIL)
95.50
Forward P/E
-6.56
Dividend (Yield %)
--

Next Event

Q3 2019 Fennec Pharmaceuticals Inc Earnings Release

Latest Developments

More

Fennec Pharmaceuticals Inc QTRLY Loss Per Share $0.24

Fennec Reports Qtrly Loss Per Share $0.13

Fennec Says Initiated Rolling New Drug Application To U.S. FDA For PEDMARK

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Fennec Pharmaceuticals Inc

Fennec Pharmaceuticals Inc., formerly Adherex Technologies Inc., is a biopharmaceutical company focused on cancer therapeutics. The Company's lead product candidate in the clinical stage of development includes Sodium Thiosulfate (STS), which has completed patient enrollment of over two Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children. STS has been studied by cooperative groups in over two Phase III clinical studies of survival and reduction of ototoxicity, The Clinical Oncology Group Protocol ACCL0431 and SIOPEL 6. The Children's Oncology Group (COG) ACCL0431 protocol enrolled 20% childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma and medulloblastoma. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.

Industry

Biotechnology & Drugs

Contact Info

68 Tw Alexander Dr

PO Box 13628

+1.919.6364530

http://fennecpharma.com

Executive Leadership

Khalid Islam

Chairman of the Board

Rostislav C. Raykov

Chief Executive Officer, Director

Robert C. Andrade

Chief Financial Officer

Shubh Goel

Chief Commercial Officer

Marco Maria Brughera

Director

Key Stats

1.67 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2017

-0.470

2018

-0.520

2019(E)

-0.747
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
5.80
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-63.33
Return on Equity (TTM)
-60.13

Latest News

BRIEF-Fennec Pharmaceuticals Reports Q1 Loss Per Share Of $0.09

* FENNEC PROVIDES BUSINESS UPDATE AND ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Fennec Pharmaceuticals Receives Breakthrough Therapy Designation By FDA For Pedmark™

* FENNEC PHARMACEUTICALS RECEIVES BREAKTHROUGH THERAPY DESIGNATION BY FDA FOR PEDMARK™

BRIEF-Fennec Says Phase 3 SIOPEL 6 Study Met Primary Endpoint

* FENNEC PROVIDES BUSINESS UPDATE AND ANNOUNCES FISCAL YEAR ENDED DECEMBER 31, 2017 FINANCIAL RESULTS

BRIEF-Fennec Pharmaceuticals Receives Fast Track Designation By FDA For Pedmark

* FENNEC PHARMACEUTICALS RECEIVES FAST TRACK DESIGNATION BY FDA FOR PEDMARK

BRIEF-Fennec Announces Pricing Of Public Offering

* SAYS PUBLIC OFFERING OF 2.35 MILLION COMMON SHARES PRICED AT $8.50PER SHARE Source text for Eikon: Further company coverage:

BRIEF-Fennec Pharmaceuticals Q3 loss per share $0.15

* Fennec provides business update and reports third quarter 2017 results

BRIEF-Fennec pharmaceuticals files for stock shelf of up to $90 mln

* Files for stock shelf of up to $90 million - SEC filing Source text (http://bit.ly/2h66FIr) Further company coverage:

BRIEF-Fennec announces positive results from phase 3 SIOPEL 6 study on Pedmark

* Fennec announces positive results from phase 3 SIOPEL 6 study on Pedmark (sodium thiosulfate) presented at the 49th Congress of the international Society of Pediatric Oncology (SIOP) 2017 meeting

BRIEF-Fennec announces preliminary results of SIOPEL 6 study on PEDMARK to be presented at SIOP meeting

* Fennec announces preliminary results of SIOPEL 6 study on PEDMARK(sodium thiosulfate) to be presented at the 49th Congress of the International Society Of Pediatric Oncology (SIOP) 2017 meeting

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up